» Articles » PMID: 35565601

Evaluation of Renal Blood Flow in Dogs During Short-Term Human-Dose Epoprostenol Administration Using Pulsed Doppler and Contrast-Enhanced Ultrasonography

Overview
Journal Animals (Basel)
Date 2022 May 14
PMID 35565601
Authors
Affiliations
Soon will be listed here.
Abstract

Prostacyclin is an in vivo bioactive substance that regulates renal blood flow (RBF). Information regarding how epoprostenol, a prostacyclin preparation, affects RBF in dogs is lacking. We investigated the effects of short-term epoprostenol administration on RBF in six healthy dogs under anesthesia by administering it intravenously at human doses-2, 5, and 10 ng/kg/min for 20 min. RBF was evaluated before and during epoprostenol administration using pulsed Doppler ultrasonography, and renal perfusion was evaluated using contrast-enhanced ultrasonography. Effects on renal and systemic circulation were evaluated by measuring systolic arterial, mean arterial, diastolic arterial, pulmonary arterial, mean right atrial, and pulmonary capillary wedge pressures; heart rate; and cardiac output. Kruskal-Wallis and Bonferroni multiple comparison tests and Spearman's rank correlation coefficient were used for statistical analyses. As epoprostenol dosage increased, the peak systolic and end diastolic velocity of the renal artery, maximum and minimum venous flow velocities of the interlobular and renal veins, and heart rate all tended to increase, although not significantly. Our results indicate that human-dose epoprostenol administration in dogs does not cause significant changes in renal or systemic circulation. However, the human doses used may have been too low to produce a clinical effect in dogs.

References
1.
Bragato N, Borges N, Fioravanti M . B-mode and Doppler ultrasound of chronic kidney disease in dogs and cats. Vet Res Commun. 2017; 41(4):307-315. DOI: 10.1007/s11259-017-9694-9. View

2.
Szczepankiewicz B, Paslawska U, Siwinska N, Plens K, Paslawski R . Evaluation of the diagnostic value of the renal resistive index as a marker of the subclinical development of cardiorenal syndrome in MMVD dogs. J Renin Angiotensin Aldosterone Syst. 2021; 22(1):1470320321995082. PMC: 8010829. DOI: 10.1177/1470320321995082. View

3.
Novellas R, Ruiz de Gopegui R, Espada Y . Effects of sedation with midazolam and butorphanol on resistive and pulsatility indices in healthy dogs. Vet Radiol Ultrasound. 2007; 48(3):276-80. DOI: 10.1111/j.1740-8261.2007.00242.x. View

4.
Fulghum T, DiMarco J, Supple E, Nash I, Gendlerman J, Eton D . Effect of prostacyclin on vascular capacity in the dog. J Clin Invest. 1985; 76(3):999-1006. PMC: 423965. DOI: 10.1172/JCI112101. View

5.
Tobimatsu M, Ueda Y, Saito S, Tsumagari T, Konomi K . Effects of a stable prostacyclin analog on experimental ischemic acute renal failure. Ann Surg. 1988; 208(1):65-70. PMC: 1493582. DOI: 10.1097/00000658-198807000-00009. View